FOR ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA IMPROVE OUTCOMES WITH SARCLISA in combination with pomalidomide + dexamethasone (Pd) vs. Pd*^1,2

ICARIA-MM: The first positive Phase 3 trial of an anti-CD38 monoclonal antibody triplet in relapsed and refractory multiple myeloma (RRMM)²

• *SARCLISA + Pd significantly increased mPFS vs. Pd alone (11.53 vs. 6.47 months, HR 0.596 [95% CI 0.44, 0.81]; p=0.001).²

INDICATION

SARCLISA is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) and have demonstrated disease progression on the last therapy.